|
|
 |
 |
| |
 Printable version |
Cost of targeted therapies in metastatic colorectal cancer |
Journal de Pharmacie Clinique. Volume 31, Number 1, 5-9, Mars 2012, Synthèse
|
 Résumé
Texte intégral
|
Author(s) : Jean-Jacques Zambrowski |
Summary : The treatment of metastatic colorectal cancer (mCRC) has improved in recent years thanks to the addition of new agents directed against angiogenesis factors or growth factor receptors to chemotherapy. If the benefit in survival is demonstrated by numerous clinical studies, the question is the relationship between this benefit and the cost of these targeted therapies. Targeted therapies have demonstrated their interest in increasing overall survival and progression-free survival in metastatic colorectal cancer. The anti-EGF-R and anti-VEGF available to date should be compared not only in terms of efficacy and safety, but also in terms of conditions of implementation and in terms of costs. As such, bevacizumab is characterized by a significantly lower price than that of other major drugs of its class. According to some analyzes, it would also offer an interesting cost-effectiveness. However, these estimates are of foreign origin, and it would be necessary to conduct similar studies in the context of French regulations. |
Keywords : colorectal cancer, targeted therapies, bevacizumab, pharmacoeconomy |
|
